Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036259991> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2036259991 abstract "In order to achieve cancer signaling network disruption and overcome primary and/or secondary resistance to standard of care agents in hematologic cancers, we have developed a novel class of dual HDAC and PI3K inhibitors by integrating a HDAC inhibitory functionality into a pharmacophore of PI3K inhibitors. Utilizing structure-based design and extensive SAR approach, CUDC-907 has been selected as a clinical candidate that inhibits not only PI3K directly but also other essential signaling pathways indirectly through epigenetic regulation following HDAC inhibition. Enzymatic assays indicate that CUDC-907 potently inhibits Class I PI3K subtypes as well as Class I and II HDAC subtypes. In anti-proliferation assays, CUDC-907 displays potent inhibition of proliferation of a variety of hematologic cancer cells (mean IC50 = 27nM in 23 cell lines). In mechanism studies, CUDC-907 potently and durably inhibits HDAC and PI3K, as indicated by increase of acetylated histone H3, inhibition of phospho-AKT and phospho-STAT3, decrease of anti-apoptotic molecules (BCL-2, survivin, etc.), and induction of P21, acetylated P53 and cleaved caspase3. CUDC-907 is orally bioavailable in animals, and displays a favorable PK profile in tumor-bearing animals. PD studies in xenograft models exhibit that CUDC-907 dose-dependently inhibits both targets, decreases tumor cell proliferation, and induces apoptosis in hematologic tumor xenografts, correlating well with its drug exposure in tumors. In efficacy studies, CUDC-907 inhibits growth of subcutaneously implanted tumor xenografts of hematologic cancers in a dose-dependent manner. Furthermore, in a Daudi NHL model, CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses. CUDC-907 also displays a favorable safety profiles. Taken together, CUDC-907 may offer greater therapeutic benefits through broad network disruption in hematologic cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C70." @default.
- W2036259991 created "2016-06-24" @default.
- W2036259991 creator A5007737148 @default.
- W2036259991 creator A5008871439 @default.
- W2036259991 creator A5015878572 @default.
- W2036259991 creator A5018703558 @default.
- W2036259991 creator A5020572091 @default.
- W2036259991 creator A5021430704 @default.
- W2036259991 creator A5031916319 @default.
- W2036259991 creator A5031922950 @default.
- W2036259991 creator A5037677450 @default.
- W2036259991 creator A5042750142 @default.
- W2036259991 creator A5044444117 @default.
- W2036259991 creator A5046246305 @default.
- W2036259991 creator A5048966000 @default.
- W2036259991 creator A5054094192 @default.
- W2036259991 creator A5054397662 @default.
- W2036259991 creator A5065104224 @default.
- W2036259991 creator A5070013569 @default.
- W2036259991 date "2011-11-12" @default.
- W2036259991 modified "2023-09-25" @default.
- W2036259991 title "Abstract C70: Antitumor activity of CUDC-907, a single small molecule inhibitor that targets both PI3K and HDAC, in hematologic cancer models." @default.
- W2036259991 doi "https://doi.org/10.1158/1535-7163.targ-11-c70" @default.
- W2036259991 hasPublicationYear "2011" @default.
- W2036259991 type Work @default.
- W2036259991 sameAs 2036259991 @default.
- W2036259991 citedByCount "0" @default.
- W2036259991 crossrefType "proceedings-article" @default.
- W2036259991 hasAuthorship W2036259991A5007737148 @default.
- W2036259991 hasAuthorship W2036259991A5008871439 @default.
- W2036259991 hasAuthorship W2036259991A5015878572 @default.
- W2036259991 hasAuthorship W2036259991A5018703558 @default.
- W2036259991 hasAuthorship W2036259991A5020572091 @default.
- W2036259991 hasAuthorship W2036259991A5021430704 @default.
- W2036259991 hasAuthorship W2036259991A5031916319 @default.
- W2036259991 hasAuthorship W2036259991A5031922950 @default.
- W2036259991 hasAuthorship W2036259991A5037677450 @default.
- W2036259991 hasAuthorship W2036259991A5042750142 @default.
- W2036259991 hasAuthorship W2036259991A5044444117 @default.
- W2036259991 hasAuthorship W2036259991A5046246305 @default.
- W2036259991 hasAuthorship W2036259991A5048966000 @default.
- W2036259991 hasAuthorship W2036259991A5054094192 @default.
- W2036259991 hasAuthorship W2036259991A5054397662 @default.
- W2036259991 hasAuthorship W2036259991A5065104224 @default.
- W2036259991 hasAuthorship W2036259991A5070013569 @default.
- W2036259991 hasConcept C104317684 @default.
- W2036259991 hasConcept C121608353 @default.
- W2036259991 hasConcept C185592680 @default.
- W2036259991 hasConcept C190283241 @default.
- W2036259991 hasConcept C41091548 @default.
- W2036259991 hasConcept C502942594 @default.
- W2036259991 hasConcept C54355233 @default.
- W2036259991 hasConcept C55493867 @default.
- W2036259991 hasConcept C56173144 @default.
- W2036259991 hasConcept C86554907 @default.
- W2036259991 hasConcept C86803240 @default.
- W2036259991 hasConcept C96232424 @default.
- W2036259991 hasConcept C98274493 @default.
- W2036259991 hasConceptScore W2036259991C104317684 @default.
- W2036259991 hasConceptScore W2036259991C121608353 @default.
- W2036259991 hasConceptScore W2036259991C185592680 @default.
- W2036259991 hasConceptScore W2036259991C190283241 @default.
- W2036259991 hasConceptScore W2036259991C41091548 @default.
- W2036259991 hasConceptScore W2036259991C502942594 @default.
- W2036259991 hasConceptScore W2036259991C54355233 @default.
- W2036259991 hasConceptScore W2036259991C55493867 @default.
- W2036259991 hasConceptScore W2036259991C56173144 @default.
- W2036259991 hasConceptScore W2036259991C86554907 @default.
- W2036259991 hasConceptScore W2036259991C86803240 @default.
- W2036259991 hasConceptScore W2036259991C96232424 @default.
- W2036259991 hasConceptScore W2036259991C98274493 @default.
- W2036259991 hasLocation W20362599911 @default.
- W2036259991 hasOpenAccess W2036259991 @default.
- W2036259991 hasPrimaryLocation W20362599911 @default.
- W2036259991 hasRelatedWork W1637270009 @default.
- W2036259991 hasRelatedWork W1963722416 @default.
- W2036259991 hasRelatedWork W1964795636 @default.
- W2036259991 hasRelatedWork W1966093917 @default.
- W2036259991 hasRelatedWork W2016090125 @default.
- W2036259991 hasRelatedWork W2022228970 @default.
- W2036259991 hasRelatedWork W2027991451 @default.
- W2036259991 hasRelatedWork W2079336580 @default.
- W2036259991 hasRelatedWork W2089728094 @default.
- W2036259991 hasRelatedWork W2410128867 @default.
- W2036259991 hasRelatedWork W2495549901 @default.
- W2036259991 hasRelatedWork W2582046956 @default.
- W2036259991 hasRelatedWork W2606253060 @default.
- W2036259991 hasRelatedWork W2739438583 @default.
- W2036259991 hasRelatedWork W2740021524 @default.
- W2036259991 hasRelatedWork W2912162934 @default.
- W2036259991 hasRelatedWork W2916665060 @default.
- W2036259991 hasRelatedWork W2971044855 @default.
- W2036259991 hasRelatedWork W3083342199 @default.
- W2036259991 hasRelatedWork W3154124461 @default.
- W2036259991 isParatext "false" @default.
- W2036259991 isRetracted "false" @default.
- W2036259991 magId "2036259991" @default.
- W2036259991 workType "article" @default.